Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
Veronique C Dieras, Mario Campone, Denise Aysel Yardley et al. · Annals of Oncology · 2015
Cited by 70 works. doi:10.1093/annonc/mdv263
Authors
- Veronique C Dieras
- Mario Campone
- Denise Aysel Yardley
- Gilles Romieu
- Vicente Valero
- SJ Isakoff
- Hartmut Koeppen
- Timothy Richard Wilson
- Yuanyuan Xiao
- David S. Shames
- Simonetta Mocci
- M. Chen
- Peter Schmid
References
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- MET signalling: principles and functions in development, organ regeneration and cancer
- Gene expression profiling of breast cell lines identifies potential new basal markers
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors